A Phase II study evaluating GSK1120212 (MEK) inhibitor alone or in combination with GSK2141795 (AKT inhibitor) in patients with metastatic endometrial cancer - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase II study evaluating GSK1120212 (MEK) inhibitor alone or in combination with GSK2141795 (AKT inhibitor) in patients with metastatic endometrial cancer

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.